Pregabalin
Pregabalin is used to treat nerve pain, fibromyalgia, and seizures. It is available as Lyrica and is commonly prescribed in the neurological category.
About Pregabalin
Pregabalin is a gabapentinoid (alpha-2-delta voltage-gated calcium channel ligand) also known by the brand name Lyrica. It is primarily used to is prescribed to treat: • Nerve pain, fibromyalgia, and Seizures.com/what is epilepsy/seizure types) • Various related conditions in the neurological category • Associated symptoms and complications It is an important medication that helps manage these conditions effectively. Pregabalin is available in oral capsule (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg), oral solution (20 mg/ml), and extended-release tablet (82.5 mg, 165 mg, 330 mg) form. Healthcare providers commonly prescribe Pregabalin for conditions including Fibromyalgia and Seizures.
Pregabalin at a Glance
- Brand names
- Lyrica
- Drug class
- Gabapentinoid (Alpha-2-Delta Voltage-Gated Calcium Channel Ligand)
- DEA schedule
- Schedule Schedule V (controlled substance)
- Pregnancy category
- FDA Category Category C — Animal studies have shown developmental toxicity at doses higher than human therapeutic exposures. Limited human data are available; pregnancy registries suggest a possible small increase in major congenital malformations. Use during pregnancy only if benefit clearly outweighs potential risk; consider alternatives when treating non-essential indications.
- Available forms
- Oral capsule (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg), Oral solution (20 mg/mL), Extended-release tablet (82.5 mg, 165 mg, 330 mg)
- Therapeutic categories
- Neurological, Anticonvulsants, Pain Management
- Conditions treated
- 2 related conditions on this site
What Pregabalin Is Used For
is prescribed to treat:
• Nerve pain, fibromyalgia, and Seizures.com/what-is-epilepsy/seizure-types) • Various related conditions in the neurological category • Associated symptoms and complications
It is an important medication that helps manage these conditions effectively.
Dosage Quick Reference
These are general dosage guidelines for Pregabalin. Your doctor will determine the appropriate dose for your specific situation.
| Condition | Starting Dose | Maintenance Dose |
|---|---|---|
| Diabetic peripheral neuropathy | 50 mg orally three times daily | Increase to 100 mg three times daily within 1 week; max 300 mg/day |
| Postherpetic neuralgia | 75 mg orally twice daily or 50 mg three times daily | Titrate to 150 mg twice daily; max 600 mg/day |
| Fibromyalgia | 75 mg orally twice daily | Increase to 150 mg twice daily within 1 week; max 450 mg/day |
| Partial-onset seizures (adjunct) | 75 mg orally twice daily | 150–300 mg twice daily; max 600 mg/day |
| Generalized anxiety disorder (off-label / non-US) | 75 mg twice daily | 150–300 mg twice daily |
| Renal impairment (CrCl < 60 mL/min) | Reduce dose proportionally | Refer to renal dosing table; titrate carefully |
Side Effects
Common side effects may include:
• Nausea or stomach upset • Headache • Dizziness or lightheadedness • Fatigue or tiredness • Mild rash or itching
Serious side effects (seek immediate medical attention):
• Severe allergic reactions (rash, hives, swelling, difficulty breathing) • Unusual bleeding or bruising • Severe stomach pain • Signs of liver problems (yellowing of skin/eyes, dark urine) • Chest pain or irregular heartbeat • Severe dizziness or fainting • Signs of serious adverse effects
See also: Drug Interactions ↓
Drug Interactions
Pregabalin is excreted essentially unchanged by the kidneys with negligible metabolism, so it has very few pharmacokinetic interactions. Most clinically important interactions are pharmacodynamic, particularly involving CNS depression.
- Opioids (e.g., oxycodone, morphine, fentanyl, tramadol): Concurrent use significantly increases the risk of respiratory depression, sedation, and overdose death. An FDA warning highlights this combination. Use the lowest doses, monitor closely, and provide naloxone in higher-risk patients.
- Benzodiazepines and other CNS depressants (e.g., alcohol, sedating antihistamines, sleep medications): Additive sedation and respiratory depression. Counsel patients to avoid alcohol and report excessive drowsiness.
- ACE inhibitors: Reports of increased risk of angioedema with concurrent use. Be alert for facial, lip, or tongue swelling, particularly in the early weeks of combined therapy.
- Thiazolidinediones (e.g., pioglitazone): Both drugs cause weight gain and peripheral edema; combination therapy may worsen these effects, particularly in patients with heart failure risk.
- Gabapentin: Mechanistically similar; concurrent use offers no added benefit and increases CNS depression. Avoid combination.
Key Considerations
Controlled substance
Pregabalin is a Schedule Schedule V controlled substance under federal law. Prescriptions are regulated, refills may be restricted, and the medication has recognized potential for misuse or dependence. Use exactly as prescribed.
Known drug interactions
Pregabalin has documented interactions with other medications, supplements, and certain foods. Review the Drug Interactions section below and tell your healthcare provider about every medication you take, including over-the-counter products. Jump to section →
Multiple forms available
Pregabalin comes in more than one form (Oral capsule (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg), Oral solution (20 mg/mL), Extended-release tablet (82.5 mg, 165 mg, 330 mg)). The right form for you depends on your condition, ease of use, and your provider's recommendation.
Additional Information
Pregabalin (Lyrica) is a gabapentinoid used for diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, neuropathic pain after spinal cord injury, and as adjunctive therapy for focal seizures. It is a federally controlled substance in Schedule V, which distinguishes it from gabapentin and reflects a recognised potential for misuse.
Mechanism of Action
Pregabalin binds the alpha-2-delta auxiliary subunit of voltage-gated calcium channels in the central nervous system. Binding reduces calcium influx into presynaptic terminals and therefore reduces release of excitatory neurotransmitters including glutamate, substance P, and norepinephrine. Despite its name and structure, it has no direct action on GABA receptors and does not alter GABA synthesis or reuptake.
The effect is largest where neurons are pathologically hyperexcitable, which is the state underlying neuropathic pain and seizure activity — so pregabalin dampens abnormal signalling without the broad sedation of a benzodiazepine.
Where pregabalin differs from gabapentin is pharmacokinetic, and the difference is clinically meaningful. Gabapentin depends on a saturable intestinal transporter, so its bioavailability falls as the dose rises and its response is correspondingly unpredictable. Pregabalin is absorbed by a high-capacity mechanism, giving it bioavailability above 90 percent and a linear, predictable dose-response. It reaches peak levels within about an hour and works at effective doses sooner, and it is dosed twice daily rather than three times.
Like gabapentin, pregabalin is not metabolised and is cleared essentially unchanged by the kidneys. Renal function therefore governs dosing entirely, and there are no meaningful hepatic drug interactions.
Clinical Use
Pregabalin has good evidence in diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia, and it is one of few drugs approved for the last of these. It is used as add-on therapy in focal seizures rather than as a first-line anticonvulsant.
Its evidence in non-neuropathic pain is weak, and this matters because it is frequently prescribed for non-specific low back pain and sciatica where trials have not shown benefit. Prescribing a gabapentinoid for undifferentiated chronic pain commonly produces sedation and dizziness without analgesia, and the resulting drug is then continued indefinitely because nobody reassessed it.
Realistic expectations improve outcomes. Pregabalin rarely eliminates neuropathic pain; a 30 to 50 percent reduction with improved sleep and function is a good result, and patients expecting resolution often abandon a drug that is working. It combines rationally with duloxetine, which acts through a different mechanism, when a single agent is insufficient.
The controlled-substance status reflects genuine misuse potential, particularly in combination with opioids, and pregabalin appears to have more euphoric effect at high doses than gabapentin does. The FDA has warned about serious respiratory depression when gabapentinoids are combined with opioids or other CNS depressants — a real risk in older adults and anyone with respiratory compromise. The MedlinePlus pregabalin entry covers the prescribing detail.
Monitoring and Follow-Up
Kidney function is the monitoring priority. Check eGFR before starting and periodically thereafter, and reduce the dose in impairment — accumulation causes sedation, confusion, unsteadiness, and myoclonus, which in older adults is regularly mistaken for cognitive decline rather than recognised as drug effect. Patients on dialysis require supplemental dosing after sessions.
No blood level monitoring is needed. What should be monitored is whether the drug is achieving the functional goal set at the start. If it is not, at an adequately titrated dose, pregabalin should be tapered off rather than continued — the alternative is a patient carrying sedation, weight gain, and edema for no analgesic return.
Weight gain and peripheral edema are common, dose-related, and frequently under-attributed to the drug. The edema is not cardiac and does not respond well to diuretics. Both are worth asking about directly, since patients often do not connect them to a pain medication. The restless legs article covers a related condition where gabapentinoids are used, and the NINDS peripheral neuropathy resource sets out the broader treatment approach. Our neurologic team manages the more complex presentations.
Pregabalin should never be stopped abruptly, particularly at higher doses or in seizure patients. Withdrawal produces anxiety, insomnia, sweating, nausea, and can precipitate seizures. Taper over at least a week, longer after prolonged use.
Special Populations
In older adults, start low and titrate slowly; falls, sedation, and confusion dominate the risk profile, and gabapentinoids appear on lists of medications to use cautiously in this group. Dose reduction for kidney function is mandatory rather than optional.
In pregnancy, human data are limited and pregabalin is used only when benefit clearly justifies it. It passes into breast milk. Combined use with opioids, benzodiazepines, or other CNS depressants markedly raises respiratory depression risk and should be avoided where possible; where unavoidable, both doses should be lower and the risk explicitly discussed. A history of substance use disorder warrants closer attention given the controlled-substance status.
The comparison with gabapentin comes up in nearly every consultation about these drugs, and the honest answer is that neither is uniformly better. Pregabalin offers predictable absorption, faster onset, and twice-daily dosing; gabapentin is not federally controlled, is generally cheaper, and has a longer track record. A patient who responded poorly to gabapentin at an apparently adequate dose may simply not have absorbed it, and is worth trying on pregabalin for that specific pharmacokinetic reason. Switching is done by dose conversion rather than by stopping one and starting the other from zero, which avoids both a gap in coverage and withdrawal symptoms.
When to Contact Your Doctor
Seek urgent care for difficulty breathing, extreme sleepiness, or unresponsiveness, particularly if you also take opioids or sedatives. Report worsening confusion, unsteadiness, or falls, which often mean the dose exceeds what your kidney function can handle. New or worsening depression, mood change, or thoughts of self-harm should be reported promptly. Significant swelling of the hands, ankles, or feet, or rapid weight gain, warrants review. Any rash with fever or facial swelling needs immediate evaluation. Never stop pregabalin abruptly on your own.
To review whether pregabalin is delivering enough benefit to justify continuing, adjust for kidney function, or discuss alternatives, contact us or schedule a visit.
Frequently Asked Questions
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.